Get Your Personalized Supplement StackSupplement Stack Quiz

Bifidobacterium breve CUL74

Also known as: B. breve CUL74, Bifidobacterium breve CUL74

Overview

Bifidobacterium breve is a species of anaerobic, Gram-positive bacteria naturally found in the human gut microbiota, particularly prevalent in infants. The CUL74 strain is a specific isolate within this species, primarily utilized as a probiotic supplement. Its main purpose is to enhance gut health, modulate the immune system, and potentially aid in the prevention or treatment of various pediatric and other health conditions. Research on B. breve strains, including CUL74, is moderately developed, with numerous preclinical animal studies and some human clinical trials. However, data specifically pertaining to the CUL74 strain is limited. Existing evidence from related B. breve strains suggests potential benefits in immune modulation, resistance against pathogens, and improvements in neonatal health and metabolic parameters. As a probiotic, it acts locally within the gut lumen and mucosa, rather than being absorbed systemically.

Benefits

While direct high-quality randomized controlled trials (RCTs) specifically on Bifidobacterium breve CUL74 are limited, benefits are inferred from closely related strains within the Bifidobacterium breve species: - **Immune modulation:** Animal studies with B. breve strains (not specifically CUL74) have shown enhanced antibody responses to viral infections, such as increased anti-influenza IgG and IgA, suggesting potential for immune support. This evidence is primarily preclinical. - **Pathogen resistance:** B. breve strains that produce exopolysaccharides (EPS) have been observed to reduce colonization by diarrheagenic pathogens in mice, indicating a protective effect on the gut barrier. This is also based on preclinical evidence. - **Neonatal health:** Systematic reviews and RCTs involving B. breve M-16V (a different strain) have demonstrated significant reductions in the incidence of necrotizing enterocolitis (NEC) and combined NEC/mortality in preterm infants. This provides strong clinical evidence for the use of B. breve in this vulnerable population. - **Metabolic effects:** The B. breve B-3 strain has shown statistically significant reductions in body fat in pre-obese adults in a randomized controlled trial, suggesting potential anti-obesity effects. This is a promising clinical finding, though from a different strain.

How it works

Bifidobacterium breve strains exert their effects primarily within the gut. They modulate the immune system by stimulating mucosal antibody production, specifically IgA and IgG, and influencing B cell responses. This is achieved through interactions with bacterial surface components, such as exopolysaccharides (EPS). EPS production also facilitates the formation of biofilms on the gut epithelium, which physically prevents the adhesion and colonization of pathogenic bacteria. Furthermore, these probiotics may interact with gut-associated lymphoid tissue, such as Peyer’s patches, to enhance overall mucosal immunity. Unlike other compounds, probiotics like B. breve CUL74 are not absorbed systemically; their beneficial actions occur locally within the gastrointestinal tract.

Side effects

Bifidobacterium breve strains, including CUL74, are generally considered safe, with no significant adverse effects reported in clinical trials, even in vulnerable populations like preterm neonates. Large studies involving B. breve strains have not reported any instances of probiotic sepsis or other serious adverse events. Common side effects are minimal and infrequent, typically limited to mild gastrointestinal symptoms such as bloating or gas. There are no documented significant drug interactions or contraindications associated with B. breve. However, individuals in special populations, such as neonates or those who are immunocompromised, should use probiotics under the supervision of a medical professional to ensure safety and appropriateness.

Dosage

Specific dosing guidelines for Bifidobacterium breve CUL74 are not well-established due to the limited clinical data available for this particular strain. However, clinical trials involving other related B. breve strains have typically utilized daily doses ranging from 10^8 to 10^10 Colony Forming Units (CFU). Administration is generally oral, and it can be taken with or without food. B. breve CUL74 is available in various formulations, including capsules, powders, or as a component of multi-strain probiotic blends. While absorption cofactors are not relevant as probiotics act locally, ensuring the survival of the bacteria through the acidic environment of the stomach is crucial for their efficacy.

FAQs

Is B. breve CUL74 effective for weight loss?

There is no direct evidence for B. breve CUL74's effectiveness in weight loss. However, a different strain, B. breve B-3, has shown modest body fat reduction in pre-obese adults in a clinical trial.

Is it safe for infants?

While specific data for CUL74 in infants is limited, other B. breve strains have demonstrated safety and efficacy in neonates, including preterm infants, in clinical studies, with no reported probiotic sepsis.

How long before effects are seen?

The timeframe for observing effects can vary. Clinical trials typically range from weeks to months. Immune and gut barrier effects, as observed in animal models, may manifest earlier.

Can it cause infections?

No probiotic sepsis or serious infections have been reported in clinical trials involving B. breve strains, indicating a favorable safety profile in this regard.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC6265827/ – This review summarizes animal and human data on Bifidobacterium breve strains, highlighting their immunomodulatory effects and ability to confer pathogen resistance in mice. It suggests potential human benefits but notes the limitation of mostly preclinical evidence and limited direct clinical data for specific strains like CUL74.
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0150775 – This retrospective cohort analysis and systematic review found that probiotic supplementation with Bifidobacterium breve M-16V significantly reduced the incidence of necrotizing enterocolitis (NEC) and combined NEC/mortality in preterm neonates. It also reported no instances of probiotic sepsis, supporting the safety and efficacy of B. breve in this vulnerable population, though it used a different strain than CUL74.
https://pubmed.ncbi.nlm.nih.gov/30094122/ – This randomized, double-blind, placebo-controlled trial involving 80 pre-obese adults demonstrated that supplementation with Bifidobacterium breve B-3 significantly reduced body fat compared to placebo over 12 weeks. While showing promising metabolic effects, it's important to note that this study used a different B. breve strain than CUL74 and had a relatively small sample size.